This announcement is a separate document:
ノイルイミューン・バイオテック：自社創薬パイプラインの優先度再設定及びそれに伴う上場時調達資金使途変更に関するお知らせ
Noile-Immune Biotech: Announcements of individual stocks regarding the re-prioritization of our in-house drug development pipeline and changes in the use of funds raised at the time of listing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.